Gene therapy for neurodegenerative diseases
- PMID: 26122838
- DOI: 10.1016/j.molmed.2015.06.001
Gene therapy for neurodegenerative diseases
Erratum in
- Trends Mol Med. 2016 Mar;22(3):266
-
Erratum to 'Gene therapy for neurodegenerative diseases' [Trends in Molecular Medicine 21 (2015) 504-512].Trends Mol Med. 2016 Mar;22(3):266. doi: 10.1016/j.molmed.2015.12.008. Epub 2016 Jan 23. Trends Mol Med. 2016. PMID: 29496034 No abstract available.
Abstract
Gene therapy is, potentially, a powerful tool for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, Parkinson's disease (PD) and Alzheimer's disease (AD). To date, clinical trials have failed to show any improvement in outcome beyond the placebo effect. Efforts to improve outcomes are focusing on three main areas: vector design and the identification of new vector serotypes, mode of delivery of gene therapies, and identification of new therapeutic targets. These advances are being tested both individually and together to improve efficacy. These improvements may finally make gene therapy successful for these disorders.
Keywords: clinical trial; gene therapy; neurodegenerative disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous